Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

About Hydroxychloroquine API

Product
  • Therapeutic Category 抗感染症

  • CAS Number

    747-36-4

  • API Technology

    Synthetic

  • Dose Form

    Oral Solids

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF

Mechanism of Action

Malaria -  The precise mechanism by which hydroxychloroquine exhibits activity against Plasmodium is not known. Hydroxychloroquine, like chloroquine, is a weak base and may exert its effect by concentrating in the acid vesicles of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA.

Rheumatoid Arthritis and Systemic Lupus Erythematosus - The mechanisms underlying the anti-inflammatory and immunomodulatory effects of PLAQUENIL are unknown.

Indication

PLAQUENIL is indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax.

PLAQUENIL is indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported.

PLAQUENIL is indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults.

PLAQUENIL is indicated for the treatment of acute and chronic rheumatoid arthritis in adults.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

ヒドロキシクロロキン

抗感染症

arrow

テルビナフィン塩酸塩

抗感染症

arrow

ポサコナゾール

抗感染症

arrow

シプロフロキサシン塩酸塩

抗感染症

arrow

ペルメトリン

抗感染症

arrow

モキシフロキサシン塩酸塩無水物

抗感染症

arrow

ガチフロキサシン

抗感染症

arrow

レボフロキサシン半水和物

抗感染症

arrow
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.